et al, 1997). The reduction in tumour blood flow leads to hypoxia in tumour tissue and might thus be a useful strategy in anti-tumour therapy in combination with other agents. For alkylating agents such as melphalan and for cytokines such as tumour necrosis factor alpha (TNF) it has been demonstrated that hypoxia can potentiate the cytotoxic effects (Skarsgard et al, 1995; de Wilt et al, 1999) .
To study the potential anti-tumour effects of systemic administration of L-NAME we used a renal subcapsular tumour model, using a colon carcinoma in WAG/Rij rats. Secondly, we examined whether addition of L-NAME to melphalan and/or TNF in an isolated limb perfusion (ILP) model could further improve response rates. For this we used a well-established perfusion model developed in our laboratory, which is based on the successful treatment of patients with in-transit metastasis from malignant melanoma (Liénard et al, 1992; Lejeune et al, 1993) and irresectable or locally advanced soft-tissue sarcoma (Eggermont et al, 1996a; . For the last group of patients TNF has recently been approved by the EMEA (European Medicine Evaluation Agency) in the ILP setting in combination with melphalan . In our ILP model strong synergistic anti-tumour effects were previously demonstrated when TNF was used in combination with two different chemotherapeutics (melphalan or doxorubicin) de Wilt et al, 1999; van der Veen et al, 2000) . The synergistic antitumour effects were accompanied by higher intratumoural melphalan concentrations after perfusion with TNF compared to perfusions with melphalan alone . The observed effects in rats corresponded well to ILP in patients in terms of response rate and histopathological observations Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions Nooijen et al, 1996) . Therefore, this rat model is applied to study usefulness of additional agents in ILP to improve response rates or find synergy between agents, which allow lower dosages of toxic agents like TNF.
MATERIALS AND METHODS

Animals
Male inbred BN and Wag/Rij rats, weighing 250-300 g, obtained from Harlan-CPB (Austerlitz, the Netherlands) were used. The rats were fed a standard laboratory diet ad libitum (Hope Farms, Woerden, the Netherlands) and were housed under standard conditions. The experimental protocols adhered to the rules outlined in the Dutch Animal Experimentation Act (1977) and the published 'Guidelines on the protection of Experimental Animals' by the council of the European Committee (1986). The protocol was approved by the committee on Animal Research of the Erasmus University Rotterdam, The Netherlands.
Drugs
Melphalan (Alkeran, 50 mg per vial, Wellcome, Beckenham, UK) was diluted in 10 ml diluent solvent. Further dilutions were made in 0.9% NaCl to give a volume of 0.2 ml in the perfusion circuit (= 40 µg). Recombinant human TNF alpha (TNF) was provided by Boehringer (Ingelheim, Germany) having a specific activity of 5.8 × 10 7 U mg -1 as determined in the murine L-M cell assay (Kramer and Carver, 1986) . Endotoxin levels were < 1.25 endotoxin units (EU) per mg protein. N ω -nitro-L-arginine methyl ester (L-NAME) (10 g per vial, Sigma, the Netherlands) was dissolved in 0.9% NaCl and administered intraperitoneally at a concentration of 80 mg kg -1 or dissolved in Haemaccel and added to the perfusate to provide a concentration of 2 mg ml -1 .
Western blot analysis for detection of inducible nitric oxide synthesis (iNOS)
Protein extracts were prepared from tissue pieces crushed under liquid nitrogen and homogenized on ice in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, 1% deoxycholate, and 0.1% SDS) containing 1 mM DTT, 0.1 mM PMSF and 10 mg l -1 aprotinin. Supernatant was prepared by centrifugation at 120 000 g for 10 min, and protein concentrations were determined with the Coomassie Plus Protein Reagent (Pierce IL, USA). Onedimensional Western blot analysis was carried out, for detection of iNOS (Towbin et al, 1979) . Briefly, sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was carried out in the Biorad minigel system with 7% polyacrylamide gel using 300 µg of soluble protein extracts. Electrophoresed proteins were transfered to a PVDF membrane (Millipore Corp, MA, USA) and unspecific binding was blocked by incubation of the membrane in TBST (10 mM Tris, 150 mM NaCl, and 0.05% Tween 20) plus 2% BSA for 1 h at room temperature. The membranes were probed with a polyclonal rabbit anti-rat iNOS antibody (N-20, Santa Cruz Biotechnology Inc, CA, USA), diluted 1:40 000 in TBST. iNOS antibody was detected using a secondary mouse antibody to rabbit which was alkaline phosphatase labelled (Sigma, St. Louis MO, USA). Colour development was performed using the alkaline phosphate substrate nitroblue tetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl-phosphate (BCIP) in AF-buffer until colour was fully developed (Boehringer Mannheim, Mannheim, Germany).
Immunohistochemical staining of tumour samples for iNOS.
Portions of BN-175 tumour samples embedded in paraffin and 4µm section were collected on clean glass slides. Slides were incubated with rabbit polyclonal anti iNOS (NOS2) antibody (N20, Santa Cruz), followed by incubation with a secondary goatanti-rabbit peroxidase conjugated antibody (Jackson ImmunoResearch Laboratories Inc, West Grove PA, USA). Colour was developed using DAB reagent according to the manufacturer (Sigma).
Renal sub-capsular tumour model
Renal sub-capsular tumour model was established in male rats of the inbred WAG-Rij strain introducing 8 mg of solid CC531 colon carcinoma under the capsule of both kidneys under microscopic vision, according to a previously described method (Marquet et al, 1984) . Treatment was started 1 day after implantation by intraperitoneal injection of 80 mg kg -1 L-NAME twice daily. Control rats were treated with a phosphate-buffered saline (PBS) solution. After 10 days of treatment rats were sacrificed and kidney tumours weighed. Both groups consisted of eight rats and all animals were evaluable. With respect to systemic toxicity of L-NAME, body weights of the rats were measured 4 and 10 days after treatment and creatinine and urea levels were determined at sacrifice.
Isolated limb perfusion model
The technique we used has been published previously . Briefly, a spontaneous, non-immunogenic BN-175 sarcoma was used and implanted subcutaneously in the right hind limb in BN rats (Kort et al, 1984) . Perfusion was performed at a tumour diameter of 13 ± 3 mm at least 7 days after implantation. Animals were anaesthetized with Hypnorm (Janssen Pharmaceutica, Tilburg, The Netherlands) and 50 IU of heparin were injected intravenously to prevent coagulation in the perfusion circuit. A warm water mattress was applied to maintain a constant temperature of 38-39°C in the hind limb during perfusion. The femoral artery and vein were cannulated with silastic tubing 0.30 mm ID, 0.64 mm OD; 0.64 mm ID 1.15 mm OD respectively, Dow Corning, Michigan, USA). Collaterals were occluded by a groin tourniquet and isolation time started when the tourniquet was tightened. An oxygenation reservoir and a roller pump were included into the circuit. The perfusion commenced with 5 ml Haemaccel (Behring Pharma, Amsterdam, the Netherlands) and the haemoglobin (Hb) content of the perfusate was 0.9 mmol l -1 . L-NAME was dissolved in the perfusate, melphalan and TNF were added as boluses to the oxygenation reservoir. A roller pump (type 505 U; Watson Marlow, Falmouth, UK) recirculated the perfusate at a flow rate of 2.4 ml min -1 . A washout with 2 ml oxygenated Haemaccel was performed at the end of the perfusion. In the rat collateral circulation via the internal iliac artery to the leg is so extensive that it allows ligation of the femoral vessels without detrimental effects. After ligation of the femoral artery back-flow from the femoral vein was seen in all rats immediately after release of the tourniquet. Subsequent tumour growth was daily recorded by calliper measurement. Tumour volume was calculated as 0.4 (A 2 B), where B represents the longest diameter and A the diameter perpendicular to B.
Assessment of tumour response
The classification of tumour response was: progressive disease (PD) = increase of tumour volume (> 25%) within 4 days; no change (NC) = tumour volume equal to volume during perfusion (in a range of -25% -+25%); partial remission (PR) = decrease of tumour volume (-25 --90%); complete remission (CR) = tumour volume 0-10% of volume during perfusion or necrosis.
Statistical analysis
Mann-Whitney U test was used to compare tumour volumes in different animal groups and to compare different tumour responses in different groups. Calculations were performed on a personal computer using GraphPad Prism and SPSS for Windows 95.
RESULTS
iNOS Western blot
Western blot analysis of tumor extracts demonstrated distinct iNOS bands at approximately M r 125 000-138 000 (Ambs et al, 1998) . iNOS was demonstrated in tumour tissue but not in muscle tissue (Figure 1) . The results suggest that iNOS is more abundant in tumour tissue than in normal muscle tissue in the rat and suggest an important role for iNOS in tumour tissue.
iNOS immunohistochemistry
The source of intratumoural NO production was determined on BN-175 tumour slides by immunohistochemistry with a polyclonal anti-NOS2 antibodies. In Figure 2 clear production of iNOS in tumour cells is shown. These results correspond with in vitro observations showing NO production by BN-175 tumour cells after stimulation with mitogens.
Renal sub-capsular tumour model
Systemic treatment with L-NAME resulted in a statistically significant growth inhibition of CC-531 colon carcinoma growing under the kidney capsule compared to untreated rats (44.8 vs 64.9 g; P < 0.005) (Fig. 3) . Ten days after treatment, body weight of rats were statistically not significantly different between both groups (-13.0 ± 5.4 g after L-NAME treatment vs -5.5 ± 3.1 g after sham (P < 0.005) and urea 5.6 ± 0.4 vs 8.1 ± 1.3 mmol l -1 (P < 0.05) in the control and L-NAME groups respectively). This increase in urea and creatinine levels indicate a decrease in renal function that might be the result of impaired renal blood flow.
Tumour response after isolated limb perfusions with L-NAME, TNF and/or melphalan
We studied the possible beneficial role of L-NAME on tumour response in ILP. Synergy between melphalan and TNF in ILP was previously demonstrated in our laboratory and could be confirmed in this study for which we used 10 rats in each study group (Table 1) (de Wilt et al, 1999; Manusama et al, 1996) . Sham perfusion did not inhibit tumour growth and progressive disease was observed in all rats. Perfusions with L-NAME as a single agent, however, resulted in tumour growth arrest after 5 days in four of 11 rats, which was statistically significant different from sham ILP (P = 0.02), resulting in a growth delay as shown in Figure 4A .
ILP with TNF alone resulted in progressive disease in all animals, similar as in sham perfused rats. Addition of L-NAME to TNF improved tumour responses from 0-64%, which was significantly different from TNF alone (P < 0.001).
After perfusion with melphalan tumour growth was arrested in eight of 10 animals (no change) and progressive tumour growth was observed in two of 10 animals. Melphalan in combination with L-NAME showed a 63% partial and complete response rate, which was significantly different from melphalan alone (P = 0.001).
TNF and melphalan have a synergistic anti-tumour effect and are highly effective with a 70% partial and complete response rate. Addition of L-NAME to the combination of TNF and melphalan, however, could further improve tumour responses to 100% 5 days after treatment, but this was not statistically significant (P = 0.3) After perfusion with TNF and melphalan recurrent tumour growth was demonstrated in all animals after a mean of 9 ± 2 days. When L-NAME was added to the perfusate one animal did not show tumour growth 50 days after ILP, whereas recurrent tumour growth occurred in nine of 10 animals after a mean of 20 ± 7 days (data not shown). The observed response rate was therefore not only more pronounced but the anti-tumour effect extended for a significantly longer period after perfusion.
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British Journal of Cancer (2000) Days after perfusion Figure 4 (A, B and C) Growth curves of BN175 sarcoma after isolated limb perfusion with sham (q; n = 10), 10 mg L-NAME (q q; n = 11), 50 µg TNF (s; n = 10), 50 µg TNF with 10 mg L-NAME (s s; n = 11), 40 µg melphalan (v; n = 10), 40 µg melphalan with 10 mg L-NAME (v v; n = 16), 50 µg TNF in combination with 40 µg melphalan (w; n = 10) and 50 µg TNF in combination with 40 µg melphalan and 10 mg L-NAME (w w) n = 10). Growth curves of sham and L-NAME perfused rats is depicted in all figures to allow comparison (mean +/-SEM of tumour volumes are shown)
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DISCUSSION
The results of the present study show a significantly reduced tumour growth after intraperitoneal administration of the nitric oxide (NO) inhibitor L-NAME in tumour-bearing rats. The growth inhibition of L-NAME in the renal sub-capsular assay may be partially due to a decrease in renal blood flow. Kassab et al (1998) previously demonstrated a decreased renal blood flow after administration of NO inhibitors, which is confirmed in our study by elevated creatinine and urea levels. Therefore, conclusions concerning anti-tumour effect of NO inhibitors from the data obtained in the renal sub-capsular assay cannot be drawn, but these data strongly suggest a growth inhibitory effect on the tumour by NO inhibitors.
In the experiments in which L-NAME was used in an isolated perfusion setting in sarcoma-bearing rats a decreased tumour growth was demonstrated when L-NAME was used alone. Moreover, strong synergy was observed when L-NAME was used in combination with either TNF (response rates improved from 0-64%) or melphalan (response rates improved from 0-63%). Even in the setting of the strongly synergistic combination of melphalan and TNF (response rates: 70%) the addition of L-NAME enhanced response rates to 100%. Moreover, when L-NAME was added to the perfusion tumour growth recurrences occurred at approximately 20 days after ILP, whereas tumours recur after a mean of 9 days after ILP with TNF and melphalan alone.
The anti-tumour effects of L-NAME in the highly vascularized BN-175 soft tissue sarcoma found in this study are similar to previously demonstrated effects of NO inhibitors in mice (Orucivic and Lala, 1996a; Thomsen et al, 1997) . The function of NO inhibition in tumour biology, however, is not clear since NO has a multifactorial role in the vascular, nervous and immune system and is demonstrated in many different cell lines and tissues. High concentrations of NO synthase (NOS) are present in different tumour cell lines, where the enzyme activity correlates with the tumour grade Ambs et al, 1998) . We demonstrated iNOS to be present in the BN-175 soft-tissue sarcoma and not in the surrounding muscle tissue using a Western blott analysis and immunohistochemistry. High levels of NO induced by iNOS suppresses metastatic potential and directly correlates with cytotoxicity in several studies (Xie and Fidler, 1999) . In contrast, Jenkins et al (1995) found a promotion of tumour growth in tumour cells that constantly produce NO. Recently others demonstrated that iNOS activity was higher in metastasizing head and neck cancer tissue compared to normal tissue, suggesting an important role for NO in tumour biology (Gallo et al, 1998) .
One mechanism of NO is to increase or maintain tumour blood flow and therefore supply nutrients and oxygen to the tumour (Buttery et al, 1993) . In studies in which rodents were treated with NO inhibitors, a selectively reduced tumour blood flow was demonstrated (Andrade et al, 1992; Tozer et al, 1997) . This decreased flow is initiated by a decreased central tumour perfusion in some tumours (Meyer et al, 1995) or a decreased peripheral perfusion in others (Fukumura et al, 1997) . Localization of NOS is cell-and tumour-dependent and as a result the response to NO inhibitor is likely to be heterogeneous and tumour-dependent. Horsman et al (1996) did not find a decrease in oxygenation status of tumours treated with NO inhibitors despite a significantly reduced tumour blood flow. However, Wood et al (1994) demonstrated that reduced flow by an NO inhibitor decreased the energy status of several murine tumours, whereas the normal skin was unaffected. Moreover, they found evidence for an increase in tumour sensitivity to a level sufficient to enhance the efficacy of cytostatic agents (Wood et al, 1994) . In vivo studies have shown that reduction of tumour blood flow with agents such as hydralazine can enhance the tumouricidal effect of melphalan. In vitro studies on human tumour cells also demonstrated a potentiation of melphalan cytotoxicity by both hypoxia and acidic pH (Skarsgard et al, 1995) . We previously demonstrated promotion of TNF as well as melphalan anti-tumour effects with hypoxia in soft-tissue sarcoma-bearing rats in ILP (de Wilt et al, 1991) . The enhanced anti-tumour effect of L-NAME with melphalan and/or TNF as we describe in this study might thus be explained by hypoxia that is induced by the reduced tumour blood flow.
More recently an important role of NO in tumour angiogenesis was suggested (Fukumura and Jain, 1998; Thomsen and Miles, 1998) . NO was shown to promote tumour progression by downregulating tissue inhibitors of metalloproteinases (TIMP) and upregulating matrix metalloproteinases (MMP) (Orucevic et al, 1999) . Gallo et al (1998) demonstrated that inhibition of NO by L-NAME in squamous cell carcinoma transplanted in the rabbit cornea decreased tumour-induced angiogensis. Similar reduced tumour angiogenesis by L-NAME was demonstrated in a highly metastatic murine breast cancer model by Jadeski and Lala (1999) . Since BN-175 is a highly vascularized and fast-growing tumour, inhibition of neovascularization in this tumour might well be a good explanation for the significant tumour responses and later re-growth after perfusion with L-NAME in combination with melphalan and TNF.
Leukocyte-endothelial interactions in tumour vessels is a major limitation of immune therapy or host immune response against tumours. NO has a possible role in down-regulating these actions and inhibition of NO was demonstrated to increase leukocyte rolling and adhesion to the vessel wall in tumours significantly (Fukumura et al, 1995) . Lejeune et al (1994) found an enhanced tumour-infiltrating lymphocyte proliferation in rat colon adenocarcinoma when NO production was inhibited with 
Tumour response
Sham Sham + LNAME TNF TNF + LNAME Melphalan Mel + LNAME TNF + Melphalan TNF + Mel + LNAME (n = 10) (n = 11) (n = 10) (n = 11) (n = 10) (n = 16) (n = 10) (n = 10)
Progressive disease 10  7  10  3  2  1  1  -No change  -4  -1  8  5  3  -Partial response  ---6  -5  1  3  Complete response  ---1  -5  6  7  Percentage response  ---64%  -63%  70%  100%  (partial/complete) Perfusions were performed with 50 µg TNF, 40 µg melphalan and 10 mg L-NAME under constant temperature (38-39°C) for 30 min L-NAME. Previous work in our laboratory and by others demonstrated that TNF-induced anti-tumour effect might be leukocyte-dependent (Renard et al, 1994; Fukumura et al, 1995; Manusama et al, 1998) . Increased leukocyte-endothelial interactions induced by L-NAME might therefore be another reason for the additional anti-tumour effect of L-NAME to TNF. Orucevic and Lala (1996b) previously demonstrated an increased antitumour effect when L-NAME was combined with another cytokine (e.g. IL-2). Meyer et al (1995) suggested that the vascular effects they observed in tumours treated with L-NAME was not only due to leukocyte adhesion but also to the development of microthrombi resulting from platelet aggregation. Since platelet aggregation is an important event in the TNF anti-tumour response as well, this mechanism might be another reason for the enhanced effect of L-NAME with TNF (Renard et al, 1995; Nooijen et al, 1996) .
In conclusion, we demonstrate that L-NAME leads to a reduction in tumour growth both after systemic administration as well as in ILP against a non-immunogenic soft-tissue sarcoma in the rat. The observed high response rates with the addition of L-NAME to melphalan and TNF are promising for the use of L-NAME in the clinical setting. Since the dose-limiting toxic effect of TNF in cancer therapy is mainly hypotension induced by NO production in endothelial cells, systemic L-NAME may favourably alter this toxicity which could result in a higher maximum tolerated dose (Kilbourn and Belloni, 1990; . This might open therapeutical options for TNF cancer treatment in other settings than in ILP. Optimization of NOS inhibitor concentrations and kinetics will be necessary to fully exploit this potential therapy.
